Oluyemi Okupe - Feb 10, 2025 Form 4 Insider Report for Hims & Hers Health, Inc. (HIMS)

Role
Chief Financial Officer
Signature
/s/ Alexandra Cotter Wilkins, Attorney-in-Fact
Stock symbol
HIMS
Transactions as of
Feb 10, 2025
Transactions value $
-$465,851
Form type
4
Date filed
2/11/2025, 04:16 PM
Previous filing
Feb 5, 2025
Next filing
Mar 5, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HIMS Class A Common Stock Options Exercise $32.2K +6.44K +5.7% $5.01 119K Feb 10, 2025 Direct F1
transaction HIMS Class A Common Stock Sale -$395K -9.19K -7.7% $42.96 110K Feb 10, 2025 Direct F1, F2
transaction HIMS Class A Common Stock Sale -$60.1K -1.39K -1.26% $43.21 109K Feb 10, 2025 Direct F1, F3
transaction HIMS Class A Common Stock Sale -$43.1K -997 -0.92% $43.23 108K Feb 10, 2025 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HIMS Stock Option (right to buy) Options Exercise $0 -6.44K -1.53% $0.00 413K Feb 10, 2025 Class A Common Stock 6.44K $5.01 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2024 by the Reporting Person.
F2 Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $42.59 - $43.345. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3 Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $43.12 - $43.345. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F4 Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $43.18 - $43.345. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F5 25% of the options will vest on the twelve (12) month anniversary of the Vesting Commencement Date of January 24, 2022. The balance of the shares shall vest in a series of thirty-six (36) successive equal monthly installments measured from the twelve (12) month anniversary of the Vesting Commencement Date, subject to optionholder's continuous Service (as defined in the Plan) as of each such vesting date.